Business Segments · Net sales of reportable segments
Cardiovascular — Net sales of reportable segments
Boston Scientific Cardiovascular — Net sales of reportable segments increased by 4.1% to $3.47B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 17.7%, from $2.94B to $3.47B. Over 4 years (FY 2021 to FY 2025), Cardiovascular — Net sales of reportable segments shows an upward trend with a 16.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ1 2020
Last reportedQ4 2025
How to read this metric
Growth indicates successful product adoption and market share expansion in cardiovascular therapies.
Detailed definition
Represents the total revenue generated from the sale of cardiovascular medical devices to external customers. It is a pr...
Peer comparison
Standard revenue reporting across all medical device and life sciences companies.
Metric ID:
bsx_segment_cardiovascular_net_sales_of_reportable_segmentsHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.87B | $1.79B | $1.90B | $1.90B | $2.07B | $2.07B | $2.13B | $2.05B | $2.18B | $2.15B | $2.25B | $2.43B | $2.63B | $2.71B | $2.94B | $3.13B | $3.34B | $3.33B | $3.47B |
| QoQ Change | — | -4.1% | +6.0% | +0.3% | +8.6% | -0.0% | +3.1% | -3.7% | +6.3% | -1.4% | +4.8% | +7.7% | +8.5% | +2.9% | +8.7% | +6.4% | +6.6% | -0.4% | +4.1% |
| YoY Change | — | — | — | — | +10.8% | +15.4% | +12.2% | +7.7% | +5.5% | +4.1% | +5.9% | +18.4% | +20.8% | +26.1% | +30.7% | +29.1% | +26.9% | +22.8% | +17.7% |
Range$1.79B – $3.47B
CAGR+14.8%
Avg YoY Growth+16.9%
Median YoY Growth+17.7%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Boston Scientific's cardiovascular — net sales of reportable segments?
- Boston Scientific (BSX) reported cardiovascular — net sales of reportable segments of $3.47B in Q4 2025.
- How has Boston Scientific's cardiovascular — net sales of reportable segments changed year-over-year?
- Boston Scientific's cardiovascular — net sales of reportable segments increased by 17.7% year-over-year, from $2.94B to $3.47B.
- What is the long-term trend for Boston Scientific's cardiovascular — net sales of reportable segments?
- Over 4 years (2021 to 2025), Boston Scientific's cardiovascular — net sales of reportable segments has grown at a 16.5% compound annual growth rate (CAGR), from $7.21B to $13.27B.
- What does cardiovascular — net sales of reportable segments mean?
- Total revenue generated by the Cardiovascular business segment.